spiperone has been researched along with Depressive Disorder, Major in 2 studies
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.
spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluvoxamine treatment significantly improved clinical symptoms and modified [(18)F]FESP binding in the frontal and occipital cortex of all of the nine patients who completed the study; in these regions a mean 31% increase in the in vivo [(18)F]FESP binding was found (P < 0." | 2.69 | Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study. ( Bonfanti, A; Colombo, C; Del Sole, A; Fazio, F; Galli, L; Gobbo, C; Lucca, A; Lucignani, G; Messa, C; Moresco, RM; Smeraldi, E, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Messa, C | 2 |
| Colombo, C | 2 |
| Moresco, RM | 2 |
| Gobbo, C | 2 |
| Galli, L | 2 |
| Lucignani, G | 2 |
| Gilardi, MC | 1 |
| Rizzo, G | 1 |
| Smeraldi, E | 2 |
| Zanardi, R | 1 |
| Artigas, F | 1 |
| Fazio, F | 2 |
| Bonfanti, A | 1 |
| Del Sole, A | 1 |
| Lucca, A | 1 |
1 trial available for spiperone and Depressive Disorder, Major
| Article | Year |
|---|---|
Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study.
Topics: Adult; Antidepressive Agents, Second-Generation; Brain; Depressive Disorder, Major; Female; Fluorine | 2000 |
1 other study available for spiperone and Depressive Disorder, Major
| Article | Year |
|---|---|
5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study.
Topics: Adult; Antidepressive Agents, Second-Generation; Brain; Case-Control Studies; Depressive Disorder, M | 2003 |